Related Experiment Videos
Neuroleptic malignant syndrome and hypothyroidism
A P Moore1, I A Macfarlane, L D Blumhardt
1Department of Neurological Science, University of Liverpool, Walton Hospital, Liverpool, United Kingdom.
Journal of Neurology, Neurosurgery, and Psychiatry
|June 1, 1990
Summary
Primary hypothyroidism may increase the risk of developing neuroleptic malignant syndrome (NMS). This thyroid condition might alter brain dopamine metabolism, potentially predisposing individuals to NMS.
Area of Science:
- Endocrinology
- Neurology
- Pharmacology
Background:
- Primary hypothyroidism is a condition involving insufficient thyroid hormone production.
- Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening reaction to antipsychotic medications.
Observation:
- Two cases of patients with primary hypothyroidism who subsequently developed NMS are presented.
- These patients experienced symptoms consistent with NMS.
Findings:
- The development of NMS in patients with hypothyroidism suggests a potential link between the two conditions.
- Altered brain dopamine metabolism in hypothyroidism may be a predisposing factor for NMS.
Implications:
- This association warrants further investigation into the role of thyroid function in NMS.
- Understanding this relationship could inform clinical practice and patient monitoring.